179 related articles for article (PubMed ID: 28802661)
21. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
[TBL] [Abstract][Full Text] [Related]
22. Isolated limb perfusion is an effective treatment modality for locally advanced Kaposi sarcoma of the extremities.
Boere T; Huis In 't Veld EA; Deroose JP; van Ginhoven TM; Wouters MWJM; Grünhagen DJ; Verhoef C; van Houdt WJ
Eur J Surg Oncol; 2020 Jul; 46(7):1315-1319. PubMed ID: 32359920
[TBL] [Abstract][Full Text] [Related]
23. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics.
Bartlett DL; Ma G; Alexander HR; Libutti SK; Fraker DL
Cancer; 1997 Dec; 80(11):2084-90. PubMed ID: 9392330
[TBL] [Abstract][Full Text] [Related]
24. Successful treatment of in-transit metastases from Merkel's cell carcinoma with isolated hyperthermic limb perfusion.
Gupta AS; Heinzman S; Levine EA
South Med J; 1998 Mar; 91(3):289-92. PubMed ID: 9521375
[TBL] [Abstract][Full Text] [Related]
25. Isolated limb perfusion with melphalan as treatment for regionally advanced melanoma of the limbs: results of 60 patients treated in Finland during 2007-2018.
Tulokas SKA; Kohtamäki LM; Mäkelä SP; Juteau S; Albäck A; Vikatmaa PJ; Mattila KE; Skyttä TK; Koivunen JP; Tyynelä-Korhonen K; Hernberg MM
Melanoma Res; 2021 Oct; 31(5):456-463. PubMed ID: 34132224
[TBL] [Abstract][Full Text] [Related]
26. Merkel cell carcinoma: report of 10 cases and review of the literature.
Akhtar S; Oza KK; Wright J
J Am Acad Dermatol; 2000 Nov; 43(5 Pt 1):755-67. PubMed ID: 11050578
[TBL] [Abstract][Full Text] [Related]
27. Long-term outcome of isolated limb perfusion with tumour necrosis factor-α for patients with melanoma in-transit metastases.
Deroose JP; Grünhagen DJ; van Geel AN; de Wilt JH; Eggermont AM; Verhoef C
Br J Surg; 2011 Nov; 98(11):1573-80. PubMed ID: 21739427
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion.
Di Filippo F; Giacomini P; Rossi CR; Santinami M; Anzà M; Garinei R; Perri P; Botti C; Di Angelo P; Sofra C; Pasqualoni R; Sperduti I; Cavaliere F; Di Filippo S; Corrias F; Armenti A; Ferraresi V; Ginebri A
In Vivo; 2009; 23(2):347-52. PubMed ID: 19414425
[TBL] [Abstract][Full Text] [Related]
29. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.
Eggermont AM; Schraffordt Koops H; Liénard D; Kroon BB; van Geel AN; Hoekstra HJ; Lejeune FJ
J Clin Oncol; 1996 Oct; 14(10):2653-65. PubMed ID: 8874324
[TBL] [Abstract][Full Text] [Related]
30. Isolated Limb Infusion: A Single-Center Experience with Over 200 Infusions.
O'Donoghue C; Perez MC; Mullinax JE; Hardman D; Sileno S; Naqvi SMH; Kim Y; Gonzalez RJ; Zager JS
Ann Surg Oncol; 2017 Dec; 24(13):3842-3849. PubMed ID: 29019175
[TBL] [Abstract][Full Text] [Related]
31. Health-Related Quality of Life for Patients Who have In-Transit Melanoma Metastases Treated with Isolated Limb Perfusion.
Bagge AS; Ben-Shabat I; Belgrano V; Olofsson Bagge R
Ann Surg Oncol; 2016 Jun; 23(6):2062-9. PubMed ID: 26868956
[TBL] [Abstract][Full Text] [Related]
32. Factors associated with response, survival, and limb salvage in patients undergoing isolated limb infusion.
Steinman J; Ariyan C; Rafferty B; Brady MS
J Surg Oncol; 2014 Apr; 109(5):405-9. PubMed ID: 24318953
[TBL] [Abstract][Full Text] [Related]
33. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas.
Deroose JP; Eggermont AM; van Geel AN; Burger JW; den Bakker MA; de Wilt JH; Verhoef C
J Clin Oncol; 2011 Oct; 29(30):4036-44. PubMed ID: 21931039
[TBL] [Abstract][Full Text] [Related]
34. Clinical Response and Regional Toxicity Following Isolated Limb Infusion Compared with Isolated Limb Perfusion for In-Transit Melanoma.
Dossett LA; Ben-Shabat I; Olofsson Bagge R; Zager JS
Ann Surg Oncol; 2016 Jul; 23(7):2330-5. PubMed ID: 26926481
[TBL] [Abstract][Full Text] [Related]
35. Response and Toxicity of Repeated Isolated Limb Perfusion (re-ILP) for Patients With In-Transit Metastases of Malignant Melanoma.
Belgrano V; Pettersson J; Nilsson JA; Mattsson J; Katsarelias D; Olofsson Bagge R
Ann Surg Oncol; 2019 Apr; 26(4):1055-1062. PubMed ID: 30617871
[TBL] [Abstract][Full Text] [Related]
36. Isolated limb perfusion in primary and recurrent melanoma: indications and results.
Liénard D; Eggermont AM; Kroon BB; Schraffordt Koops H; Lejeune FJ
Semin Surg Oncol; 1998; 14(3):202-9. PubMed ID: 9548602
[TBL] [Abstract][Full Text] [Related]
37. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma.
Grunhagen DJ; de Wilt JH; Graveland WJ; Verhoef C; van Geel AN; Eggermont AM
Cancer; 2006 Apr; 106(8):1776-84. PubMed ID: 16541435
[TBL] [Abstract][Full Text] [Related]
38. The Effect of Temperature and Perfusion Time on Response, Toxicity, and Survival in Patients with In-transit Melanoma Metastases Treated with Isolated Limb Perfusion.
Katsarelias D; Rådbo E; Ben-Shabat I; Mattsson J; Olofsson Bagge R
Ann Surg Oncol; 2018 Jul; 25(7):1836-1842. PubMed ID: 29766389
[TBL] [Abstract][Full Text] [Related]
39. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593.
Koops HS; Vaglini M; Suciu S; Kroon BB; Thompson JF; Göhl J; Eggermont AM; Di Filippo F; Krementz ET; Ruiter D; Lejeune FJ
J Clin Oncol; 1998 Sep; 16(9):2906-12. PubMed ID: 9738557
[TBL] [Abstract][Full Text] [Related]
40. One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases.
Grünhagen DJ; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
Ann Surg; 2004 Dec; 240(6):939-47; discussion 947-8. PubMed ID: 15570199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
